Some Infants With Focal Hyperinsulinism Improve Without Surgery
A third of focal congenital hyperinsulinism cases showed spontaneous glycemic improvement, raising questions about routine surgical intervention.
Summary
Congenital hyperinsulinism is the leading genetic cause of dangerously low blood sugar in newborns. The focal form, caused by a small abnormal patch of pancreatic tissue, is typically treated with surgery. In a retrospective review of 39 infants treated at a French referral center, researchers found that roughly 30% showed rapid early improvement without requiring continuous tube feeding to maintain blood sugar. Among this milder group, four children were completely cured before age six without any surgery at all. Surgical cure rates were high — 96–100% — and long-term complications were uncommon, mainly affecting those who had pancreatic head surgery. Researchers also developed a predictive scoring tool with 97% specificity to identify which infants might improve early, potentially allowing more selective use of surgery in carefully chosen cases.
Detailed Summary
Congenital hyperinsulinism (CHI) is the most common genetic cause of persistent low blood sugar in infants and, if untreated, can lead to irreversible brain injury. The focal form — caused by a localized cluster of abnormal insulin-secreting cells in the pancreas — is potentially curable with targeted surgery. However, pancreatic surgery, especially involving the head of the pancreas, carries risks including exocrine pancreatic insufficiency and other postoperative complications. This study asks whether surgery is always necessary, and whether some infants might safely improve on their own.
Researchers at Necker-Enfants Malades Hospital in Paris retrospectively reviewed records of 39 infants with confirmed focal CHI. They divided patients into two groups based on severity: those who required continuous tube feeding to maintain safe blood glucose levels (TF group, 69%) and those who did not (NTF group, 31%). This practical severity classification helped reveal meaningful clinical differences between subgroups.
Key findings were notable. Infants in the NTF group were diagnosed later and had less severe initial hypoglycemia. Crucially, four of the 12 NTF patients never required surgery and were confirmed free of hypoglycemia by age six. Surgery was highly effective when performed, achieving cure in 96.3% of TF patients and 100% of NTF patients who underwent the procedure. Long-term complications were rare overall, but exocrine pancreatic insufficiency occurred in 15.8% of those who had pancreatic head resections — a meaningful risk that merits consideration.
The researchers developed an exploratory predictive scoring tool to identify infants likely to show early spontaneous improvement, achieving 97% specificity. This could help clinicians stratify risk and potentially defer surgery in selected low-severity cases.
These findings suggest that a conservative, watchful-waiting approach may be appropriate for a subset of infants with focal CHI, particularly when the lesion is in the pancreatic head — where surgical risk is highest. However, the retrospective single-center design and small sample size limit generalizability, and the predictive score requires prospective validation before clinical adoption.
Key Findings
- About 30% of focal CHI infants showed rapid early glycemic improvement without requiring continuous tube feeding.
- 4 of 12 milder-severity infants achieved complete cure of hypoglycemia before age 6 without surgery.
- Surgery was curative in 96–100% of cases when performed, with low long-term complication rates.
- Exocrine pancreatic insufficiency occurred in 15.8% of patients after pancreatic head surgery.
- A new predictive scoring tool identified early improvers with 97% specificity, pending validation.
Methodology
This was a retrospective single-center cohort study of 39 infants with confirmed focal congenital hyperinsulinism at a French referral center. Patients were stratified by need for continuous tube feeding as a proxy for disease severity. An exploratory predictive score for early disease evolution was developed from the dataset.
Study Limitations
The summary is based on the abstract only, as the full text was not accessible. The retrospective single-center design and small sample of 39 patients limit generalizability. The predictive scoring tool is exploratory and requires prospective multicenter validation before routine clinical use.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.